Which federal agency does National Association of Chain Drug Stores comment on most?

National Association of Chain Drug Stores is most active at the Food and Drug Administration.

← OpenPolis Sign in

National Association of Chain Drug Stores

Unclaimed

Industry

Nonprofit Organization Management

Staff

1776 Wilson Blvd, Arlington, Virginia

Phone

+1 703-549-3001

Website

nacds.org

Engagement overview

National Association of Chain Drug Stores has filed 174 public comments across 152 dockets at 15 federal agencies, most actively at the Food and Drug Administration.

National Association of Chain Drug Stores

Engagement overview

Is this your organization?

Agency footprint

Dockets (152)

Increasing Availability of Nonprescription Drugs; Request for Information

Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure

Developing Specifications for In-Home Disposal Systems for Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

FTC Seeks Analysis To Aid Public Comment on Agreement Containing Consent Order; Express Scripts; Docket No. 9437

Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions To Unleash Prosperity

Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, Medical Equipment, and Their Parts and Components

Draft FTC Strategic Plan for FY 2026-2030

Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

Proposed Modifications to the HIPAA Security Rule to Strengthen the Cybersecurity of ePHI

Enhancing Coverage of Preventive Services under the Affordable Care Act

Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

Request for Information on Consolidation in Health Care Markets

Medication Guides: Patient Medication Information; Proposed Rule

Request for Information; Coverage of Over-the-Counter Preventive Services

Advisory Committee on Immunization Practices meeting September 22, 2023

In-Home Safe Disposal Systems; Request for Information

Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing

Medications for the Treatment of Opioid Use Disorder

Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; Request for Comments

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

Nondiscrimination in Health Programs and Activities

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Solicitation for Public Comments on the Impact of Prescription Benefit Managers’ Business Practices

Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

COVID-19 Vaccination and Testing Emergency Temporary Standard Rulemaking

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

Advisory Committee on Immunization Practices (ACIP) August 24, 2021

ACIP COVID-19 August 13, 2021 Meeting

Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices

Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments

Advisory Committee on Immunization Practices (ACIP)

Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information.

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Instructions for Use -- Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products -- Content and Format; Draft Guidance for Industry; Availability

Modernizing Ignitable Liquids Determinations

Nonproprietary Naming of Biological Products

Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability

Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses CMS-4180-P

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Medicaid and Children’s Health Insurance Plan (CHIP) Managed Care (CMS-2408-P)

Future Format of the National Drug Code; Public Hearing; Request for Comments

Insanitary Conditions at Compounding Facilities

Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products Between the States and the Food and Drug Administration; Revised Draft; Availability

Product Identifiers Under the Drug Supply Chain Security Act Questions and Answers; Draft Guidance for Industry

Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Innovative Approaches for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Waivers of the Single, Shared System Risk Evaluation and Mitigation Strategy Requirement

Development of a Shared System Risk Evaluation and Mitigation Strategy

Medicaid Program: Methods for Assuring Access to Cover Medicaid Services- Exceptions for States With High Managed Care Penetration Rates and Rate Reduction Threshold. (CMS-2406-P)

Increasing Recycling: Adding Aerosol Cans to the Universal Waste Regulations

Enhanced Drug Distribution Security under the Drug Supply Chain Security Act; Public Meetings; Request for Comments

Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act

Opioid Policy Steering Committee prescribing intervention – exploring a strategy for implementation; Public Hearing; Request for Comments

Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff; Availability

Patent Extension Application for Trulance™ U.S. Patent No. 7,041, 786

Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs For Contract Year 2019 CMS-4182-P

Opioid Policy Steering Committee

Review of Existing General Regulatory and Information Collection Requirements of the Food and Drug Administration

Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019 (CMS-9930-P)

Identifying Trading Partners Under the Drug Supply Chain Security Act

Administering the Hatch-Waxman Amendments: Ensuring an Appropriate Balance Between Innovation and Access

Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018; Medicare Shared Savings Program Requirements; and Medicare Diabetes Prevention Program (CMS-1676-)

Product Identifier Requirements Under the Drug Supply Chain Security Act-Compliance Policy

Amendment to the Universal Waste Rule: Addition of Pharmaceuticals

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids

Training for Opioid Analgesic Prescribers--Exploring the Path Forward